marked.bio

anti-PD-L1 antibody · antibody

KL-A167

2 active trials across 2 of our biomarkers, targeting PD-L1. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 1 1 Phase 2
MSI-H / dMMR 1 1 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of KL-A167.

  1. Kelun-Biotech 1

Trials

2 of 2 trials shown

  1. SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies

    Not yet recruiting Phase 2 Peking Union Medical College Hospital Started 2026Primary completion 2028-09 NCT07738757

    sacituzumab tirumotecanKL-A167

    3\. dMMR or MSI-H subtype (defined as: deficiency/loss of mismatch repair (MMR) proteins MLH1, PMS2, MSH2, …

    MSI-H / dMMRRecurrent or Metastatic MSI-H/dMMR Gynecological Malignancies

  2. SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

    Recruiting Phase 2 Kelun-Biotech Started 2022Primary completion 2026-08 NCT05351788

    sacituzumab tirumotecanKL-A167carboplatincisplatin

    Cohort 3: Patients with locally advanced/metastatic NSCLC with EGFR activating mutation and negative ALK fusion gene, who have failed previous treatment with EGFR-TKIs.

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer